Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG

Read more

Convalescent Plasma Is A Potentially Effective Treatment Option for Patients Hospitalized With COVID 19, According to Early Data

Patients hospitalized with COVID-19 who received convalescent plasma demonstrated improved survival and were more likely than matched control patients to remain the same or have improvements in their supplemental oxygen requirements, according to a study conducted by researchers at the Icahn School of Medicine at Mount Sinai and published today on pre-print server medRxiv.

Read more

Calcium Signaling Identified as Exploitable Target in Addressing Drug Resistance to Non-Hodgkin Lymphoma Treatment

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.

Read more